Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Patient's With Renal Impairment

Ureter Injury Clinical Trial

Official title:

An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06085183
• Other study ID #: PVP-22IC05
• Status: Recruiting
• Phase: Phase 4
• Start date: December 20, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: January 2024
• Source: Prove pharm
• Contact: Michelle Boytim, P.hD.
• Phone: 610-850-7115
• Email: michelle.boytim[@]provepharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.

Description:

An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease (MDRD) and standardized by using individual's body surface area as described in the FDA's Renal Impairment guidance. Qualified subjects/patients will be stratified into 4 cohorts based on their eGFR at baseline: patients with normal renal function (eGFR ≥ 90 mL/min), patients with mild (eGFR 60-89 mL/min), moderate (eGFR 30-59 mL/min) and severe (eGFR 15-29 mL/min) renal impairment.

Up to ten study centers in the United States will enroll up to approximately 12 subjects per cohort (48 subjects in total) scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive covering the full renal function range from normal, mild, moderate, and severe renal impairment. For each subject/patient the study will consist of a screening period (Day -30 to Day -2), a baseline evaluation (Day -1 to Day 1) and a single treatment period (Day 1) with an onsite observation period of 24 hours post-dose. After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit.

On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by cohort and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). All randomized subjects will serve as his/her own control (i.e., intra-patient controlled) for efficacy by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose. The surgeon will be blinded to the Bludigo™ dose a subject receives. Time of injection of saline and Bludigo™ will be captured.

All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28.

Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects between = 18 and = 85 years old

• Subjects who signed a written IRB approved, informed consent form

• Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure.

• An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease formula (MDRD) and standardized by using individual's body surface area.

Subject's renal function will be defined based on the following criteria:

• Normal subjects: eGFR of =90 mL/min

• Mild renal impairment: eGFR 60 to 89 mL/min

• Moderate renal impairment: eGFR 30 to 59 mL/min

• Severe renal impairment: eGFR 15 to 29 mL/min

Subjects with normal renal function that are judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests performed at the Screening Visit and/or prior to administration of study drug.

Patients with renal impairment (mild, moderate, or severe) who have a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal insufficiency meeting criteria at the Screening Visit

Exclusion Criteria:

• Subjects with eGFR <15 mL/min or expected need for dialysis in the near future, or having only 1 kidney

• Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes

• Known history of drug or alcohol abuse within 6 months prior to the time of screening visit

• Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g., major systemic diseases)

• Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures

• Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

• Subjects with life expectancy < 6 months

• Requirement for concomitant treatment that could bias primary evaluation.

• Subjects who are pregnant or breast-feeding

Related Conditions & MeSH terms

• Renal Insufficiency
• Ureter Injury

Intervention

Other:
• Saline Injection 0.9%
Placebo

Drug:
• Indigotindisulfonate sodium 0.8%
Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Locations

Country	Name	City	State
United States	Albany Medical Center	Albany	New York

Sponsors (1)

Lead Sponsor	Collaborator
Prove pharm

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score	An exploratory comparison will be performed to assess the difference between the Bludigo™ high dose vs Bludigo™ low dose in urine jet conspicuity score.; The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed; = Weak jet, little color contrast; = Color contrast or significant jet flow; = Strong jet flow with good color contrast; = Strong jet flow with striking contrast in color	10 to 15 minutes post study drug administration
Other	Impact of renal impairment on renal elimination of Bludigo™	An exploratory comparison will be performed to assess the impact of renal impairment on renal elimination of Bludigo™.	12 hours post study drug administration
Other	Urinary excretion of Bludigo in patients with and without renal impairment	An exploratory assessments of the amount of Bludigo excreted in urine in patients with and without renal impairment.	12 hours post study drug administration
Primary	Paired sample difference (Bludigo - Saline) in urine jet conspicuity score.	Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed; = Weak jet, little color contrast; = Color contrast or significant jet flow; = Strong jet flow with good color contrast; = Strong jet flow with striking contrast in color; Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer.	10 to 15 minutes post study drug administration
Primary	Responders to Bludigo	Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed; = Weak jet, little color contrast; = Color contrast or significant jet flow; = Strong jet flow with good color contrast; = Strong jet flow with striking contrast in color; A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer.	10 to 15 minutes post study drug administration
Secondary	Incidence of adverse events and serious adverse events.	Percentage of patients in each treatment group who experience an adverse event post treatment	30 days post study drug administration
Secondary	Changes in clinical safety laboratory values	Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment	30 days post study drug administration
Secondary	Changes in vital signs post treatment	Proportion of subjects with clinically important changes in vital signs after treatment	30 days post study drug administration
Secondary	Changes in ECG post treatment	Proportion of subjects with clinically important changes in ECGs after treatment	30 days post study drug administration
Secondary	Changes in blood pressure by dose group and Renal Impairment Cohort	Comparison of post treatment changes in blood pressure by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)	30 days post study drug administration
Secondary	Changes in heart rate by dose group and Renal Impairment Cohort	Comparison of post treatment changes in heart rate by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)	30 days post study drug administration
Secondary	Changes in pulse oximetry by dose group and Renal Impairment Cohort	Comparison of post treatment changes in pulse oximetry by dose group and renal impairment cohort (normal renal function, mild, moderate, and severe impairment)	30 days post study drug administration
Secondary	Time to visualization	To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment	10 to 15 minutes post study drug administration
Secondary	Physician Satisfaction	To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement: "Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™."; = Strongly Agree; = Agree; = Neither Agree nor Disagree; = Disagree; = Strongly Disagree A surgeon's evaluation is considered satisfactory if the rating is either a 1 (strongly agree) or 2 (agree).	10 to 15 minutes post study drug administration